The Pharmaletter

One To Watch

splicebio-large-1

SpliceBio

A Spanish genetic medicines company utilising protein splicing to develop the next generation of gene therapies.

The company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of protein engineering research.

Want to Update your Company's Profile?


More SpliceBio news >